NMTR

Stats

Summary

9 meters biopharma, inc., a clinical-stage biotechnology company, focuses on patients with rare disorders and unmet needs. the company's pipeline includes drug candidates for short bowel syndrome (sbs) and celiac disease. it is developing nm-002, a long-acting injectable glp-1 agonist that is in a phase 2 clinical trial for sbs; and larazotide, a phase 3-stage therapeutic in development for celiac disease. the company also develops nm-003, a proprietary long-acting glp-2 agonist; and nm-004, a double-cleaved mesalamine with an immunomodulator for developing rare and/or orphan indications. 9 meters biopharma, inc. is based in raleigh, north carolina.

Market Cap: 1.83 Million

Primary Exchange: NASDAQ

Website: http://www.innovatebiopharma.com/

Shares Outstanding: 14.5 Million

Float: 0

Dividend: 0.0 (0.0%)

Beta: 0.9430671847673433

Sector: Manufacturing

Industry: Computer Storage Device Manufacturing

Ethical Flags

Longest drawdown: 573 trading days

From: 2021-02-16 To: 2022-10-14

Lowest Point:

Ex-Date	Payment Date	Record Date	Declared Date	Amount	Flag	Dividend Type	Qualified	Indicated

Ex-Date	Declared Date	Record Date	Payment Date	Ratio	To Factor	For Factor